The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted two positive opinions for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union.
